Chronic hypoxia-induced PAH

IPST employs four preclinical models of induced pulmonary arterial hypertension. Each is characterized by defined underlying phenomena, and is best suited to specific pathologies and associated treatments.

Chronic hypoxia involves maintaining the animals in low-FiO2 conditions for 14-21 days to induce pulmonary arterial hypertension.

The remodelling is smooth-muscle based, characterized by chronic vasoconstriction leading to hypertrophy and hyperplasia of the vascular smooth muscle cells.

Unlike Monocrotaline, there is no endothelial damage or inflammatory component in chronic hypoxia-induced pulmonary arterial hypertension. The remodeling is reversible, can be dialed-in to a desired severity, and is in itself non-lethal, unless pushed to extremes.

The functional parameters measured on the animals monitor all the systems within the animal, and are complemented by a full-scale histopathological examination of the lung’s vasculature.

IPST’s chronic hypoxia systems allow simultaneous treatment of approximately 100 animals at a time. Typical experimental group size is 10 animals.